Hyperion DeFi, Inc.
HYPD
Get informed when a big investor buys or sells
+ FollowMarket Cap$51.54M
Close$
Share Statistics
| Market cap | $51.54 Million |
|---|---|
| Enterprise Value | $-673,760,660.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.4 |
| Beta | 2.52 |
| Outstanding Shares | 14,173,457 |
Return
| Return on Equity | -37.39% |
|---|---|
| Return on Assets | -33.69% |
| Return on Invested Capital | -35.26% |
Valuation & Multiples
| P/E Ratio | -1.09 |
|---|---|
| PEG | 0.24 |
| Price to Sales | 0.06 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -0.83 |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -13.23 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$2.24
Average shareholder expectationRevenue Estimate
$1.27 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$2.31
Average shareholder expectationRevenue Estimate
$2.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eyenovia Inc
33 employees
CEO: Hyunsu Jung Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.